Comprehensive molecular characterization of human colon and rectal cancer

Nature

MedicineColorectal CancerPathologyHuman ColonOncology +3

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, +14

New England Journal of Medicine

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Christos S. Karapetis, Shirin Khambata‐Ford, Derek J. Jonker, +13

New England Journal of Medicine

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre, +10

Cancer Research

Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging

J. B. O'Connell, Melinda A. Maggard, Clifford Y. Ko

JNCI Journal of the National Cancer Institute

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, +8

Journal of Clinical Oncology

Kras MutationsGastrointestinal OncologyMedicineBraf MutationsImmunology +11

Colorectal carcinoma: Pathologic aspects.

Matthew R. Fleming, Sreelakshmi Ravula, Sergei Tatishchev, +1

PubMed

Tumor BiologySurgical OncologyGastrointestinal OncologyColorectal SurgeryMedicine +13

Comparison of 17,641 Patients With Right- and Left-Sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival

Frank Benedix, Rainer Kube, Frank Meyer, +3

Diseases of the Colon & Rectum

Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

Gordon Hutchins, Katie Southward, Kelly Handley, +8

Journal of Clinical Oncology

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau, +14

Journal of Clinical Oncology